Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sc ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sc ...

"Morayo" Became the Highest Streamed Album Debut Ever for an African Artist Recent Releases from Splitmind Include Major Collaborations with GloRilla, Brent Faiyaz, KYLE, Russ, and Blxst Drumify Achieves Record Revenues for October Drumify to Launch First Generative A1 Platform for Beats and Sounds with Seekr and Intel Partnership LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) -- LiveOne, Inc. (NASDAQ: LVO), a leader in the entertainment landscape, is thrilled to announce its subsidiary Splitmind has executive ...

Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration (“FDA”) Premarket Approval Application (“PMA”) Supplement approval for the Oxford Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (“IDE”) study and non-clinical testing for cementless partial knee replacement (“PKR”).With this, Oxford Cementless Partial Knee becomes the only FDA-approved cementless partial knee implant in the United States. The latest FDA ...

文章核心观点 - Cassava Sciences, Inc. (SAVA) 近期股价下跌83.9%，但因处于超卖状态且分析师普遍上调盈利预期，股价可能即将反弹 [1][5][6][7] 超卖股票的识别方法 - 使用相对强弱指数 (RSI) 识别超卖股票，RSI低于30通常被视为超卖 [2] - RSI帮助投资者快速判断股价是否接近反转点，即使基本面良好，股价也会在超买和超卖之间波动 [3] SAVA的技术分析 - SAVA的RSI读数为21.7，表明卖压可能正在减弱，股价有望反弹 [5] - SAVA的Zacks排名为2 (买入)，表明其基于盈利预期修订和EPS惊喜的排名位于前20%，进一步支持股价反弹的潜力 [7] SAVA的基本面分析 - 分析师在过去30天内将SAVA的当前年度盈利预期上调了36.3%，通常这种上调趋势会转化为股价的短期上涨 [6]

After reaching an important support level, Luxfer (LXFR) could be a good stock pick from a technical perspective. LXFR surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages.Like other SMAs, i ...

文章核心观点 - 公司预测Nvidia将在AI芯片市场中继续保持主导地位，并预计其将超过第三季度的预期 [1] 研究方法 - 公司采用严谨的研究驱动方法，挖掘在动态行业如大科技、半导体、AI和医疗领域中具有强劲增长潜力的股票 [2] - 公司分析包括低风险和高风险选择的投资机会，这些机会有潜力表现优异 [2] - 每个投资理念都基于深入研究和战略远见，旨在帮助投资者在复杂市场中导航并获得强劲回报 [2] 投资策略 - 公司提供结合创新和高潜力的复杂股票选择 [2]

At a P/E of 10 after its sell-off, Kohl's stock looks cheap.Kohl's (KSS -20.15%) stock collapsed after the company reported mixed earnings for its fiscal third quarter of 2024 Tuesday morning, falling 20% in the first 10 minutes of trading, as of 9:40 a.m. ET.Analysts forecast Kohl's would book $3.7 billion in sales for the third quarter ended Nov. 2, and Kohl's nailed that target. Unfortunately, they also forecast Kohl's would earn $0.27 per share -- but Kohl's earned only $0.20. Adding to investors' distr ...

Alnylam Pharmaceuticals (ALNY) announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Amvuttra (vutrisiran) for review to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Amvuttra, an RNAi therapeutic, is ALNY’s lead drug, which is currently approved in the United States for treating adult patients with polyneuropathy of transthyretin-mediated (hATTR) amyloidosis. It is also marketed in the EU for treating hATTR amyloidosis in adult patients with ...

From a technical perspective, Dream Finders Homes Inc. (DFH) is looking like an interesting pick, as it just reached a key level of support. DFH recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend.Shares of ...